·
9 MIN READ

June 2, 2023: National Advocacy Update

U.S. Surgeon General releases advisory on social media and youth mental health, and more in the latest National Advocacy Update.

Advocacy Update
·
12 MIN READ

Cannabis side effects for senior and older adult patients with Alison Moore, MD, MPH

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about the risks of cannabis for seniors.

series
Public Health
AMA Update
·
12 MIN READ

Cannabis side effects for senior and older adult patients with Alison Moore, MD, MPH

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about the risks of cannabis for seniors.

series
Public Health
AMA Update Podcast
·
10 MIN READ

May 19, 2023: National Advocacy Update

 Senate Committee passes bipartisan PBM legislation and more in the latest National Advocacy Update.

Advocacy Update
Narcan nasal spray
·
4 MIN READ

Narcan lands OTC approval: What it means for patients, doctors

The drug’s manufacturer and retailers must help ensure the lifesaving opioid overdose-reversal medication is widely available at an affordable price. 

Overdose Epidemic
·
11 MIN READ

CDC Chief Medical Officer Deb Houry, MD, on the next phase of COVID-19 data, vaccines and care

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about the next phase of COVID-19 data, vaccines and care.

series
Public Health
AMA Update
·
11 MIN READ

CDC Chief Medical Officer Deb Houry, MD, on the next phase of COVID-19 data, vaccines and care [Podcast]

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about the next phase of COVID-19 data, vaccines and care.

series
Public Health
AMA Update Podcast
·
5 MIN READ

May 5, 2023: State Advocacy Update

Push for prior authorization reforms continue in the states and more in the latest State Advocacy Update.

Advocacy Update
·
1 MIN READ

AMA statement on DEA extending telehealth prescription flexibilities

The AMA applauds the DEA extending flexibilities in the prescribing of controlled substances through telehealth visits through Nov. 11, 2023.

Press Releases